Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.

SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated...

Full description

Bibliographic Details
Main Authors: Serena Marchi, Simonetta Viviani, Edmond J Remarque, Antonella Ruello, Emilio Bombardieri, Valentina Bollati, Gregorio P Milani, Alessandro Manenti, Giulia Lapini, Annunziata Rebuffat, Emanuele Montomoli, Claudia M Trombetta
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0253977
id doaj-0919a58c67494a3f8b32fb73ff404f99
record_format Article
spelling doaj-0919a58c67494a3f8b32fb73ff404f992021-07-16T04:31:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025397710.1371/journal.pone.0253977Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.Serena MarchiSimonetta VivianiEdmond J RemarqueAntonella RuelloEmilio BombardieriValentina BollatiGregorio P MilaniAlessandro ManentiGiulia LapiniAnnunziata RebuffatEmanuele MontomoliClaudia M TrombettaSARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.https://doi.org/10.1371/journal.pone.0253977
collection DOAJ
language English
format Article
sources DOAJ
author Serena Marchi
Simonetta Viviani
Edmond J Remarque
Antonella Ruello
Emilio Bombardieri
Valentina Bollati
Gregorio P Milani
Alessandro Manenti
Giulia Lapini
Annunziata Rebuffat
Emanuele Montomoli
Claudia M Trombetta
spellingShingle Serena Marchi
Simonetta Viviani
Edmond J Remarque
Antonella Ruello
Emilio Bombardieri
Valentina Bollati
Gregorio P Milani
Alessandro Manenti
Giulia Lapini
Annunziata Rebuffat
Emanuele Montomoli
Claudia M Trombetta
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
PLoS ONE
author_facet Serena Marchi
Simonetta Viviani
Edmond J Remarque
Antonella Ruello
Emilio Bombardieri
Valentina Bollati
Gregorio P Milani
Alessandro Manenti
Giulia Lapini
Annunziata Rebuffat
Emanuele Montomoli
Claudia M Trombetta
author_sort Serena Marchi
title Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
title_short Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
title_full Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
title_fullStr Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
title_full_unstemmed Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
title_sort characterization of antibody response in asymptomatic and symptomatic sars-cov-2 infection.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2021-01-01
description SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.
url https://doi.org/10.1371/journal.pone.0253977
work_keys_str_mv AT serenamarchi characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT simonettaviviani characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT edmondjremarque characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT antonellaruello characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT emiliobombardieri characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT valentinabollati characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT gregoriopmilani characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT alessandromanenti characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT giulialapini characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT annunziatarebuffat characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT emanuelemontomoli characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
AT claudiamtrombetta characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection
_version_ 1721297923281518592